{"id":"W1892175722","doi":"10.1111/bjd.14018","title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":322,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Janssen Biotech; Allergan; LEO Pharma; Genentech; Celgene; Novartis; Pfizer; ApoPharma; Boehringer Ingelheim; Amgen; AbbVie; Merck; Abbott Laboratories; Eli Lilly and Company","keywords":"Tofacitinib; Janus kinase inhibitor; Placebo; Medicine; Adverse effect; Psoriasis; Internal medicine; Randomized controlled trial; Plaque psoriasis; Gastroenterology; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01149321,0.001781069,0.003157617,0.0005166149,0.0005552383,0.001779564,0.001069013,0.00214695,0.005841935],"category_scores_gemma":[0.00900602,0.000602587,0.004198307,0.0008588683,0.0008737652,0.001103677,0.0005024488,0.002291085,0.0006386263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106045,"about_ca_system_score_gemma":0.001867082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008011253,"about_ca_topic_score_gemma":0.002076551,"domain_scores_codex":[0.9971129,0.00160578,0.0003562593,0.0003436443,0.0003687754,0.0002127318],"domain_scores_gemma":[0.9946136,0.001976632,0.001763528,0.0003634267,0.000550144,0.0007325868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8934429,0.006502055,0.002389591,0.005562372,0.008948058,0.0000671265,0.0001448335,0.0003936347,0.005317142,0.0001554806,0.003164344,0.07391245],"study_design_scores_gemma":[0.9444656,0.03750434,0.007477082,0.0004386371,0.00601505,0.0001094228,0.00003774312,0.0001735225,0.0006727321,0.000169378,0.002905652,0.00003073347],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.769685,0.1899308,0.003904999,0.005667901,0.001804749,0.01353648,0.007548,0.0003631224,0.007558957],"genre_scores_gemma":[0.9051706,0.06589696,0.004647326,0.004356924,0.001718538,0.009068013,0.006088374,0.00009247282,0.002960871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01149321,"threshold_uncertainty_score":0.06078261,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04869677487528288,"score_gpt":0.3168638201301229,"score_spread":0.26816704525484,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}